EXECUTIVE SUMMARY

• Aclarion Expands CLARITY Multicenter Trial Site to University of Arizona – Phoenix: Aclarion added the University of Arizona College of Medicine – Phoenix as a key clinical investigative site for its pivotal CLARITY clinical trial, evaluating magnetic resonance spectroscopy (NOCISCAN-LS) to objectively identify painful disc levels in chronic low back pain patients.
• AlloPort Announces Launch of Allograft Access Platform for Hospitals and Tissue Banks: AlloPort announced its public platform launch ahead of the AATB Annual Conference, standardizing procurement workflows and expanding hospital access to accredited musculoskeletal allografts.
• Kinematic Alignment Demonstrates Superior Gait Restoration in CPAK Type 1 Knee Phenotypes: Comparative clinical research published in MDSpire News confirms that restricted kinematic alignment (rKA) in CPAK Type 1 (constitutional varus) total knee arthroplasty achieves superior post-operative gait symmetry and reduces ligamentous releases compared to mechanical alignment.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Diagnostics

Aclarion — Expands Pivotal CLARITY Trial to University of Arizona College of Medicine – Phoenix

• Summary: Aclarion, Inc. announced the addition of the University of Arizona College of Medicine – Phoenix as an active clinical trial site for its ongoing CLARITY study. The prospective multicenter study evaluates the diagnostic efficacy of NOCISCAN-LS, a proprietary post-processing magnetic resonance spectroscopy (MRS) software platform that analyzes chemical biomarkers (such as lactic acid and proteoglycan ratios) within lumbar intervertebral discs. By quantifying biochemical disc degeneration, the platform provides objective diagnostic data to help spine surgeons identify which specific disc levels are generating discogenic low back pain prior to performing fusion or disc arthroplasty.
• Key Details:
• Device/System Name: NOCISCAN-LS Magnetic Resonance Spectroscopy Platform
• Status: Multicenter Clinical Trial Expansion (CLARITY Study)
• Clinical Significance: Provides objective biochemical biomarker data to improve surgical target selection, reducing non-specific fusion rates and improving patient-reported pain relief in chronic discogenic back pain.
• Original Source: Aclarion Clinical Trial Update — Orthopedics This Week

Joint Reconstruction (Hip, Knee, Shoulder)

Total Knee Arthroplasty — Kinematic Alignment Outperforms Mechanical Alignment in CPAK Type 1 Phenotypes

• Summary: Clinical comparative data published in MDSpire News evaluated gait symmetry and functional kinematics following total knee arthroplasty (TKA) categorized by Coronal Plane Alignment of the Knee (CPAK) phenotypes. The study demonstrated that patients with CPAK Type 1 anatomy (constitutional varus joint line and apex distal alignment) who received restricted kinematic alignment (rKA) experienced significantly faster restoration of native gait patterns and quadriceps strength, while requiring significantly fewer soft-tissue releases compared to those aligned with traditional neutral mechanical alignment.
• Key Details:
• Device/System Name: Restricted Kinematic Alignment (rKA) Knee Arthroplasty Protocols
• Status: Clinical Comparative Study Analysis
• Clinical Significance: Preserves native constitutional knee joint obliquity, minimizing soft-tissue trauma and accelerating post-operative gait rehabilitation.
• Original Source: MDSpire Orthopedic Medicine Report

Biologics & Tissue Banking

AlloPort — Prepares Public Launch to Expand Hospital and Tissue Bank Access to Orthopaedic Allografts

• Summary: AlloPort announced its planned public launch scheduled for September 1, 2026, ahead of its formal industry presentation at the American Association of Tissue Banks (AATB) Annual Conference in San Francisco. The digital procurement network connects accredited non-profit and commercial tissue banks directly with hospital surgical supply chains and ambulatory surgery centers (ASCs), providing real-time inventory visibility and streamlined ordering for structural bone allografts, osteochondral grafts, and soft-tissue tendon constructs.
• Key Details:
• Device/System Name: AlloPort Digital Allograft Procurement Network
• Status: Commercial Platform Launch
• Clinical Significance: Reduces lead times and logistical barriers for subspecialty surgeons requiring specialized structural bone and tendon allografts in revision joint and complex sports medicine procedures.
• Original Source: AlloPort Launch Announcement — Orthopedics This Week

Corporate, M&A & Industry Metrics

Medtronic — Declares Second-Quarter Cash Dividend for Fiscal Year 2027

• Summary: Medtronic plc announced that its Board of Directors approved a second-quarter cash dividend of $0.70 per ordinary share for fiscal year 2027. The declaration reflects stable operational cash generation and sustained capital reinvestment across Medtronic's Cranial & Spinal Technologies division and Mazor™ robotic surgical systems.
• Key Details:
• Device/System Name: Corporate Dividend Declaration
• Status: Board Approved
• Clinical Significance: Demonstrates steady capital stability and continuous long-term R&D funding for spinal robotics, navigation, and enabling technologies.
• Original Source: Medtronic Financial Announcement on OrthoGlobe

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)